Objective: To evaluate the impact of policy and practice changes in prenatal screening for Down's syndrome(DS) on prenatal diagnosis and livebirth prevalence of DS.
Introduction
Prenatal diagnosis for Down's syndrome has made considerable progress in the past twenty years 1;2 . In particular, techniques using maternal serum and ultrasonographic markers have provided non-invasive antenatal screening tests for Down's syndrome. This has been especially important for younger women who are at lower risk of Down's syndrome, and hence usually not candidates for invasive diagnostic procedures, but who nevertheless often account for the majority of Down's syndrome cases due to the size of their population.
Along with technical progress in antenatal screening, public policies on screening have been adopted in several European countries 3 . In particular, a policy of general offer of serum screening for all women is to be implemented in England in 2004 4 . France has pursued an active national policy for prenatal screening of Down's syndrome 5;6 . In recent years, prenatal diagnosis of Down's syndrome has expanded considerably from a system essentially based on offering amniocentesis to women 38 years of age or those with significant family history of chromosomal abnormalities to a regulated system of universal access to both ultrasound and maternal serum screening. This process came about as a result of important changes in the policy for prenatal testing introduced in 1988 with increasing use of ultrasound and reimbursed amniocentesis in case of ultrasound abnormalities suggesting the presence of a chromosomal anomaly and the introduction of maternal serum screening in the early 1990's with its widespread use after 1997. Finally, the use of nuchal translucency measurement became widespread beginning in 1996.
The current policy for antenatal screening in France includes: i) nuchal translucency measurement as a matter of routine between 11-13 weeks of gestation, ii) maternal serum screening between 14 and 16 weeks (cut-off level 1/250), which should be systematically proposed to all women as stated by a law implemented in January 1997, and iii) a morphological scan at around 22 weeks of gestation for all women. Costs of antenatal screening are reimbursed and in the case of a positive result in any of the screening tests, amniocentesis is proposed and its costs are reimbursed. In addition, reimbursed amniocentesis (or chorionic villus sampling) is available to all women 38 years of age and older. In the event of a prenatal diagnosis of Down's syndrome, or in general any "serious illness, recognised as incurable at the time of diagnosis" 7 , termination of pregnancy is allowed regardless of gestational age.
The primary goals of this policy are to increase prenatal detection of Down's syndrome in order to maximise the options available to pregnant women and to allow an informed choice about prenatal testing 8 . Few studies have evaluated the impact of these policies at the Maternal age was missing for 15 cases (0.8%). Data for prenatal testing were not available for the first two years of the registration. Therefore, the proportion of cases detected prior to birth was calculated only for the period 1983-2000. During this period, data on prenatal testing were missing for 5 cases (0.3%). Miscarriage cases were excluded in the analysis of trends for the proportion of cases detected prior to birth.
Total prevalence was calculated as the total number of Down's syndrome cases (live births + stillbirths + terminations of pregnancy) per 10,000 births. Live birth prevalence was defined as the number of Down's syndrome live births per 10,000 live births. Cases considered detected prior to birth included all those with prenatal cytogenetic confirmation, as well as, 32 cases diagnosed after birth for which results of ultrasound and/or serum screening had suggested the need for an amniocentesis, which nonetheless was not undertaken based on women's wishes.
Statistical Analysis
We used binomial regression models 10 to assess time trends in the proportion of Down's syndrome cases detected prior to birth. Maternal age-adjusted risk ratios with 95%
confidence intervals were calculated to compare the probability of Down's syndrome detected prior to birth in the three periods corresponding to major changes in the practice and policy of prenatal testing in France: 1) prior to 1989, cytogenetic examination for high risk groups We used Poisson regression models 11 to analyse time trends in total and live birth prevalence of Down's syndrome. In the analysis of trends in total prevalence of Down's syndrome, expected foetal loss rate after prenatal diagnosis was adjusted using estimates suggested by Cuckle 12 .
We assessed the overall annual trends, as well as, piece-wise linear estimates of the annual trends in the livebirth prevalence of Down's syndrome in the three periods 1981 -1988, 1989 -1995 and 1996 -2000 . Marginal piecewise coefficients were obtained, which represent the change in the slope from the preceding period; e.g., change in the annual trend in live birth prevalence observed in 1989 -1995 as compared with 1981 -1988. Goodness-of-fit tests were done to assess evidence of any overdispersion (extra-Poisson variation). We did not find any evidence of significant lack of fit. Results of the annual trends in the total and live birth prevalence of Down's syndrome are reported in terms of prevalence ratios (PR) with 95% confidence intervals. All statistical analyses were done using the STATA 13 statistical software.
Results

Trends in the proportion of cases detected prior to birth
Overall, the proportion of cases of Down's syndrome that were detected prior to birth increased by about nine-fold for women < 38 years of age; from 9.5% (95% CI, 2. Table 1 ). The net effect of these trends was that the proportion of cases of Down's syndrome detected prior to birth in women less than 38 years of age approached that of women 38 years of age or greater by the year 2000 ( Figure 1 ).
Trends in total and live birth prevalence of Down's syndrome (Figure 2)
During the study period, there was a substantial trend towards delayed childbearing in the study population. For example, the proportion of women > 35 years of age increased from 11.1% (95% CI, 10. 
Discussion
In summary, the proportion of Down's syndrome cases detected prenatally increased substantially in the past two decades. This was particularly the case for younger women. By far most of the cases of Down's syndrome were detected prior to birth by the year 2000.
Consequently, the live birth prevalence of Down's syndrome decreased in the 1990s despite the consistent trends towards delayed childbearing 14 . Taken together these trends suggest that the progress in screening techniques, together with the active national policy for antenatal screening in France, have had a major impact both on prenatal detection and the livebirth prevalence of Down's syndrome.
Recently, it has been suggested that maternal serum screening and ultrasound might preferentially detect foetuses that are lost prior to birth 15 . Hence, the impact of screening on live birth prevalence of Down's syndrome might be lower than would otherwise be predicted.
In our study, the crude (unadjusted) live birth prevalence of Down's syndrome decreased on average by about 3% per year over the study period; but live birth prevalence did not change appreciably before 1990. It should be noted however that these trends came about against the background of consistent increases in delayed childbearing and consequently simultaneous increases in the total birth prevalence of Down's syndrome. This was also reflected in the ageadjusted estimate of the annual rate of decrease in live birth prevalence of Down's syndrome, which was 13% as compared with 3% for the unadjusted estimate. Hence, notwithstanding the possibility of a preferential detection by prenatal screening of foetuses that are lost prior to birth, our results suggest that there was a major impact on live birth prevalence of Down's syndrome as a result of the increases in prenatal detection of Down's syndrome.
An important caveat that needs to be considered in the interpretation of our findings is that as an observational study of time trends, our study cannot establish a definitive causal link between the adopted policies and the rate of increase in prenatal detection of Down's syndrome. However, considering the particularly high rate of increase in the prenatal detection of Down's syndrome among younger women, it seems reasonable to assume that the progress in the ultrasonographic and maternal serum techniques for antenatal screening together with the policies adopted to ensure equal access to reimbursed screening for all women in France have had a major impact on prenatal detection of Down's syndrome. The effects of the policy however might differ across geographic regions in France as the amniocentesis rates are higher in Paris than in the rest of the country 16;17 .
Another caveat is that our study population might have changed over time in ways that might significantly affect our findings. In order to assess the possible impact of any such bias (including referral bias), we examined the trends in prenatal detection of Down's syndrome by limiting the study population to residents of Paris who gave birth or had a termination of pregnancy in Parisian maternity units (i.e., excluding both women from the surrounding suburbs in the Greater Paris area and elsewhere). The results of these analyses of trends in prenatal detection of Down's syndrome were essentially identical to those presented here for the Greater Paris area.
In addition to its impact on detection rates or live birth prevalence, a complete evaluation of a screening policy also requires consideration of the costs of the program, including the rate of invasive diagnostic procedures and the associated risks of foetal loss. Our data do not allow evaluation of trends in these indices, in particular in the amniocentesis rates.
Recent data suggest that the rate of amniocentesis is approximately 11% in France 16 and 16%
in the Parisian population 17 . These rates are substantially higher than those reported for England 4 and the United States 18 .
It has been suggested that introduction of antenatal screening might provide an opportunity for decreasing the rate of amniocentesis, particularly among older women 19;20 .
However, many women in France who are eligible for reimbursed serum screening, and in particular those with higher levels of education, obtain amniocentesis without serum screening 21 . This might limit the use of antenatal screening as a solution to the growing number of amniocenteses. However, as the sensitivity of prenatal screening strategies increases 1 , pregnant women might be increasingly likely to use antenatal screening and forego an amniocentesis in case of negative screening results.
Broader considerations in the evaluation of antenatal screening programs include assessment of issues related to the potentially negative effects of widespread screening on the perceptions about individuals with Down's syndrome and the services that might be available for their care. Indeed, a critique of prenatal testing has been its potential for reinforcing discriminatory views about individuals with disabilities 22 . Concerns have also been raised about the choices and the services available to women who might not wish to opt for prenatal testing, if such testing comes to be viewed as the norm 23 . Given our data and comparable findings from another population 24 that suggest almost 90% of the cases of Down's syndrome might currently be detected and often terminated prior to birth, future studies and policies should also address the potentially negative consequences of widespread use of prenatal testing for individuals born with Down's syndrome and other congenital anomalies.
Conclusions
By far most cases of Down's syndrome are currently detected prenatally in the Parisian population. Consequently, the livebirth prevalence of Down's syndrome has decreased despite consistent trends towards delayed childbearing. These positive public health effects have to be balanced against a relatively high rate of amniocentesis and the potentially negative 
